Carlsmed (CARL) Common Equity (2024 - 2026)

Carlsmed (CARL) has reported Common Equity for 3 consecutive years, with $84.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 201.41% year-over-year to $84.2 million; the trailing twelve-month figure through Jun 2026 stood at $84.2 million (up 201.41% YoY), and the FY2025 full-year result was $98.9 million, up 239.98% from the prior year.
• Common Equity slipped to $84.2 million in Q2 2026 per CARL's latest filing, from $92.2 million in the prior quarter.
• Across five years, Common Equity topped out at $106.7 million in Q3 2025 and bottomed at -$83.1 million in Q2 2025.
• Historically, Common Equity has averaged $3.1 million across 3 years, with a median of -$57.7 million in 2024.
• The widest YoY moves for Common Equity: up 261.54% in 2025, down 43.88% in 2025.
• Over 3 years, Common Equity stood at -$70.6 million in 2024, then jumped by 239.98% to $98.9 million in 2025, then declined by 14.79% to $84.2 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $84.2 million, $92.2 million, and $98.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.